These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19393953)

  • 1. Poor-quality medicines in developing countries.
    Ravinetto RM; Cloëz S; Scouflaire-Mallet SM; Vandenbergh D
    Lancet Infect Dis; 2009 May; 9(5):267-8. PubMed ID: 19393953
    [No Abstract]   [Full Text] [Related]  

  • 2. [Quality of medicines in least developed countries].
    Videau JY
    Med Trop (Mars); 2006 Dec; 66(6):533-7. PubMed ID: 17286015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WHO wants safer medicines for children.
    Choonara I
    Arch Dis Child; 2008 Jun; 93(6):456-7. PubMed ID: 18495908
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of an association in promoting pharmaceutical quality assurance: transfer of know-how based on the buddy system].
    Ba A; Courcambeck A; Degui H
    Med Trop (Mars); 2006 Dec; 66(6):538-41. PubMed ID: 17286016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New countermeasures considered as drug counterfeiting grows.
    Schubert C
    Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of poor-quality medicines in the 'developing' world.
    Newton PN; Green MD; Fernández FM
    Trends Pharmacol Sci; 2010 Mar; 31(3):99-101. PubMed ID: 20117849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The primacy of public health considerations in defining poor quality medicines.
    Newton PN; Amin AA; Bird C; Passmore P; Dukes G; Tomson G; Simons B; Bate R; Guerin PJ; White NJ
    PLoS Med; 2011 Dec; 8(12):e1001139. PubMed ID: 22162953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counterfeiting and piracy of pharmaceuticals.
    Grackin A
    IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698
    [No Abstract]   [Full Text] [Related]  

  • 10. WHO and industry combine to form ethics body.
    Dickson D
    Nat Med; 2002 Jul; 8(7):645. PubMed ID: 12091885
    [No Abstract]   [Full Text] [Related]  

  • 11. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-third report.
    World Health Organ Tech Rep Ser; 1993; 834():1-30. PubMed ID: 8362524
    [No Abstract]   [Full Text] [Related]  

  • 12. Use caution when donating drugs, guidelines suggest.
    Riggs B
    CMAJ; 1990 Jan; 142(1):65-6. PubMed ID: 2293855
    [No Abstract]   [Full Text] [Related]  

  • 13. An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products.
    Babu PV
    Biologicals; 2011 Sep; 39(5):300-3. PubMed ID: 21816621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is quality of medicines?
    Doogue MP; Thynne TR
    Intern Med J; 2013 Oct; 43(10):1057-8. PubMed ID: 24134167
    [No Abstract]   [Full Text] [Related]  

  • 15. Substandard and counterfeit medicines.
    Rassool GH
    J Adv Nurs; 2004 May; 46(3):338-9. PubMed ID: 15119344
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of the incidence of substandard drugs in developing countries.
    Verduin-Muttiganzi R; Verduin-Muttiganzi G
    Trop Med Int Health; 1998 Jul; 3(7):602. PubMed ID: 9705197
    [No Abstract]   [Full Text] [Related]  

  • 17. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2012; (970):1-235, back cover. PubMed ID: 22894011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global health-care implications of substandard medicines.
    Senior K
    Lancet Infect Dis; 2008 Nov; 8(11):666. PubMed ID: 18992395
    [No Abstract]   [Full Text] [Related]  

  • 20. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.